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approach. Bare metal stents were used in 2 pa‑
tients (8.3%) (LD Max, EV3, Plymouth, Min‑
nesota, United States and Cheatham Platinum, 
NuMED, Inc., Hopkinton, New York, United 
States), and covered stents were used in the re‑
maining 22 pa tients (83.7%) (Cheatham Plati‑
num, NuMED, Inc.).
Written informed consent was obtained from 
all patients before the intervention. In accor‑
dance with national ethics regulations, approv‑
al for further analysis was not required as this 
was a retrospective study with anonymized pa‑
tient data.
Statistical analysis Statistical analysis was 
performed using SPSS 17.0 (SPSS Inc., Chica‑
go, Illinois, United States). Normally distrib‑
uted continuous variables were compared 
with the paired ‑sample t  test, and categori‑
cal variables, with the Wilcoxon signed ‑rank 
test. A P value of less than 0.05 was considered 
significant.
Results and conclusions The median age 
at procedure was 36 years (range, 18–77 years). 
All patients underwent successful stent implan‑
tation, with a significant reduction in peak sys‑
tolic pressure gradient (TABLE 1). The maximal re‑
sidual pressure gradient was 6 mm Hg. The me‑
dian hospitalization time was 4 days (lower 
and upper quartiles, 3 and 5 days,  respectively). 
No early procedure ‑related complications, such 
as neurologic deficit, stent migration, balloon 
rupture, or aortic wall injury, were observed. 
Introduction Coarctation of the aorta (CoA) 
is a common cause of secondary arterial hyper‑
tension in young adults.1,2 However, in many cas‑
es, antihypertensive therapy is initiated with‑
out excluding this condition, and hypertension 
is very likely to persist. We aimed to analyze 
the diagnostic pathway and medical therapy of 
hypertension in adult patients undergoing en‑
dovascular stenting of CoA.
Methods We investigated 24 consecutive 
adults (men, 78.1%) with CoA referred for 
a transcatheter intervention at our institution 
between May 2013 and April 2018. Medical his‑
tory was obtained at baseline, with special at‑
tention paid to the age at which hypertension 
was first noted and the age at final diagnosis of 
CoA. Detailed information on antihypertensive 
therapy was collected at baseline, at discharge, 
and then by phone after a mean (SD) period of 
34 (17) months (range, 2–63 months).
Blood pressure (BP) was measured at baseline 
and after stenting, using an Omron oscillomet‑
ric device (Omron Healthcare, Kyoto, Japan). 
Hypertension was defined in accordance with 
the European Society of Cardiology guidelines.1
Endovascular procedures were carried out 
under general anesthesia in a hybrid operating 
room. Invasive measurement of aortic BP was 
performed above and below the coarctation di‑
rectly before and after stenting. Peak systolic 
pressure gradient defined as a difference in peak 
systolic BP measured across the lesion was cal‑
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when possible: 6 patients (26.1%) were dis‑
charged without any antihypertensive medica‑
tion, 10 (52.2%) were prescribed 1 or 2 antihy‑
pertensive drugs, and 7 (30.4%) were prescribed 
at least 3 drugs. The mean number of drugs per 
patient dropped from 3.1 to 1.9 (TABLE 1).
At follow ‑up, 15 patients (65.2%) continued 
their medication, but only 7 (30.4%) required 
3 drugs or more. The mean number of drugs per 
patient was similar to that at discharge (TABLE 1).
Coarctation of the aorta was diagnosed in ad‑
olescence or adulthood in 20 patients (83.3%). 
Among the 4 patients diagnosed in infancy, 2 were 
operated on before the age of 3 years and current‑
ly presented due to recoarctation. In the case of 
the remaining 2 patients, surgery was deferred 
at the request of their caregivers, and, eventu‑
ally, percutaneous intervention was performed 
at the age of 35 and 27 years, respectively. In this 
subgroup, the first clinical manifestation of CoA 
was predominantly hypertension (in 19 patients), 
while cardiac murmur was reported as the first 
recognized symptom in 1 patient. The mean (SD) 
age at detection of these abnormalities was 17.1 
(8.8) years (range, 1–36 years), while the mean 
(SD) age at diagnosis of CoA was 33.5 (14.9) years 
(range, 15–60). These calculations did not include 
1 patient who died, as complete information could 
not be obtained. The mean (SD) delay in diagnosis 
was 16.4 (11.1) years (maximum 37 years).
Importantly, the majority of patients did not 
undergo proper physical examination either be‑
fore or during medical treatment (continued for 
nearly 11 years on average, maximally 25 years). 
Coarctation of the aorta can often be diagnosed 
only on physical examination. A discrepancy be‑
tween upper and lower extremity pulses, and, 
more importantly, a difference in BP between up‑
per and lower limb of more than 20/10 mm Hg, 
are highly suggestive findings.1,2 Unfortunate‑
ly, pulse assessment and 4‑limb BP measure‑
ment, although quick and easy to perform, seem 
to be neglected by many physicians. In fact, all 
patients from our group claimed to have been 
prescribed medication without prior evaluation 
of femoral pulses. Four ‑limb pressure measure‑
ment was performed before referral to a tertia‑
ry care hospital only in 2 patients.
Published data confirm that correction of CoA 
leads to BP reduction.3-5 De ‑escalation or dis‑
continuation of antihypertensive therapy may 
be achieved in 63% to 84% of patients after 
stenting.5-8 These data are in accordance with 
our study, where reduction in the number of 
drugs was observed in 60.1% of patients at dis‑
charge and 69.6% at follow ‑up. Residual hyper‑
tension may be due to arterial remodeling result‑
ing from diffuse vasculopathy involving, among 
others, the transforming growth factor ‑β sig‑
naling pathway.3,9
Endovascular stenting has become an accept‑
ed therapeutic option in adults with CoA.6,8,10 
One patient died 14 days after the procedure 
from decompensated acute heart failure caused 
by de novo aortic valve stenosis. However, this 
was not considered a complication of stenting. 
In 1 of the 2 patients treated with bare metal 
stents, aortic aneurysm formation was revealed 
during the follow ‑up. A successful implanta‑
tion of a covered stent (CVRDCP8Z39, NuMED, 
Inc.) into the previously implanted bare metal 
stent (CP8Z45, NuMED, Inc.) was performed 11 
months after the index procedure.
At baseline, only 1 patient (4.2%) did not take 
any antihypertensive drugs, while the majority 
(79.2%) were treated with at least 3 drugs. A sig‑
nificant decrease in both systolic and diastol‑
ic BP was observed after the procedure (TABLE 1). 
Medical treatment was reduced or discontinued 
TABLE 1 Invasive and noninvasive blood pressure measurement as well as use 
of antihypertensive drugs before stent implantation (baseline), after the procedure 
(discharge), and at follow ‑up
Parameter Baseline Discharge Follow ‑up
Invasive blood pressure measurement
No. of patients 24 24 NA
Ascending aorta 
SBP, mm Hg
115.5 (31.7) 111.7 (24.5)
P = 0.55 (95% CI, –9.2 to 16.8)a
Descending aorta 
SBP, mm Hg
81.0 (23.3) 110.4 (23.6) NA
P <0.001 (95% CI, –42.4 to –16.4)a
Peak systolic pressure 
gradient, mm Hg
40.1 (15.9) 1.3 (2.2) NA
P <0.001 (95% CI, 32.1–45.4)a
Noninvasive blood pressure measurement (upper extremity)
No. of patients 24 23 NA
SBP, mm Hg 155.8 (20.0) 131.1 (17.2)
P <0.001 (95% CI, 16.7–32.6)a
DBP, mm Hg 84.2 (11.2) 78.6 (10.1) NA
P = 0.04 (95% CI, 0.2–11.1)a
Antihypertensive drugs
No. of patients 24 23 23
At least 1 drug, n (%) 23 (95.8) 17 (73.9) 15 (65.2)
P = 0.025 (Z = –2.24)a NA
P = 0.008 (Z = –2.65)b
At least 3 drugs, n (%) 19 (79.2) 7 (30.4) 7 (30.4)
P = 0.001 (Z = –3.46)b
Average number of drugs 
per patient
3.1 (1.3) 1.9 (1.8) 1.9 (1.7)
P = 0.01 (95% CI, –2.1 to –0.3)a NA
P = 0.009 (95% CI, –2.1 to –0.3)b
Data are presented as mean (SD) unless indicated otherwise.
a comparison of baseline with discharge data;  b comparison of baseline with follow ‑up data
Abbreviations: SBP, systolic blood pressure, DBP, diastolic blood pressure; NA, not applicable
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We believe that apart from reporting satisfac‑
tory results in terms of safety, efficacy, and res‑
olution of hypertension, our study highlights 
the need for careful physical examination. Pal‑
pation of brachial and femoral pulses as well 
as BP measurement in the upper and lower ex‑
tremities should constitute an integral part of 
routine medical checkup in patients presenting 
with hypertension to avoid unnecessary medica‑
tion and late complications of long ‑lasting un‑
recognized CoA.
The limitations of our single ‑center study in‑
clude selection bias, since we analyzed a relative‑
ly small number of patients treated in a tertiary 
cardiac center for adults. Furthermore, follow ‑up 
was short due to the patients’ expected life span, 
and the follow ‑up data were based on phone 
contact. Finally, a standardized method of BP 
measurement, preferably 24‑hour ambulatory 
BP measurement, should be used to objectively 
confirm the efficacy of medication.
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